US Patent Issued to JIANGSU HENGRUI MEDICINE, SHANGHAI HENGRUI PHARMACEUTICAL on Sept. 2 for "Antibody capable of binding to thymic stromal lymphopoietin and use thereof" (Chinese Inventors)

ALEXANDRIA, Va., Sept. 3 -- United States Patent no. 12,404,323, issued on Sept. 2, was assigned to JIANGSU HENGRUI MEDICINE Co. LTD (Lianyungang, China) and SHANGHAI HENGRUI PHARMACEUTICAL Co. LTD (Shanghai).

"Antibody capable of binding to thymic stromal lymphopoietin and use thereof" was invented by Jinping Shi (Shanghai), Hua Ying (Shanghai), Tingting Li (Shanghai), Yifang Wang (Shanghai), Guimei Yang (Shanghai), Hu Ge (Shanghai) and Weikang Tao (Shanghai).

According to the abstract* released by the U.S. Patent & Trademark Office: "Disclosed are an antibody capable of binding to thymic stromal lymphopoietin and the use thereof. Disclosed are an anti-TSLP antibody, comprising a murine antibody, chimeric antibody and humanized antibody ...